DHMEQ racemate


Catalog No. Size PriceQuantity
M25712-C Contact sales@xcessbio.com for quotation $100Unavailable

Description

DHMEQ racemate is a NF-κB inhibitor. DHMEQ racemate is less active than (-)-DHMEQ.

Product information

CAS Number: 287194-38-1

Molecular Weight: 261.23

Formula: C13H11NO5

Chemical Name: 2-hydroxy-N-[(1S,6S)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]benzamide

Smiles: OC1=CC=CC=C1C(=O)NC1=CC(=O)[C@H]2O[C@H]2C1O

InChiKey: IUOMATKBBPCLFR-SAIIYOCFSA-N

InChi: InChI=1S/C13H11NO5/c15-8-4-2-1-3-6(8)13(18)14-7-5-9(16)11-12(19-11)10(7)17/h1-5,10-12,15,17H,(H,14,18)/t10?,11-,12+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 32 mg/mL (122.50 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

DHMEQ racemate (DHM3EQ) and (-)-DHMEQ (DHM2EQ) inhibits TNF-a-induced NF-kB activation. (-)-DHMEQ is more potent and less toxic than DHMEQ racemate.

In Vivo:

The antiarthritic effects of (-)-DHMEQ (DHM2EQ) and DHMEQ racemate (DHM3EQ) are examined on type-II collagen-induced arthritis in DBA1/J mice. This animal model is widely used for evaluation of antirheumatic drugs because of its pathological similarities to human rheumatoid arthritis. The arthritis is elicited and scored. (-)-DHMEQ markedly inhibits type-II-collagen-induced arthritis in mice, whereas DHMEQ racemate tends to only slightly inhibit it.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

You may also like

Recently viewed